Determination of aniracetam and its main metabolite, N-anisoyl-GABA, in human plasma by high-performance liquid chromatography.
Two different reversed-phase high-performance liquid chromatographic methods for the determination of aniracetam (I) and its metabolite N-anisoyl-GABA (II) in human plasma are described. The procedure for I involves direct injection of plasma samples spiked with the internal standard on a clean-up column followed by reversed-phase chromatography on a C18 column. The limit of quantification was 5 ng/ml, using a 200-microliters specimen of plasma. The mean inter-assay precision of the method up to 800 ng/ml was 3%. The procedure for II involved liquid-liquid extraction of II and the internal standard from plasma with ethyl acetate, and reversed-phase chromatography on a C18 column. The limit of quantification was 50 ng/ml using a 0.5-ml plasma specimen. The mean inter-assay precision up to 50 micrograms/ml was 6%. The applicability and accuracy of the methods were demonstrated by the analysis of over 1000 plasma samples from two bioavailability studies in healthy volunteers.
Guenzi
A
A
Pharmacokinetics Laboratory, Prodotti Roche S.p.A., Milan, Italy.
Zanetti
M
M
D000840:Anisoles / Q000097:blood* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007202:Indicators and Reagents; D011760:Pyrrolidinones / Q000097:blood* / Q000493:pharmacokinetics; D011786:Quality Control; D013056:Spectrophotometry, Ultraviolet
D000840:Anisoles; D007202:Indicators and Reagents; D011760:Pyrrolidinones; C036466:aniracetam; C067664:N-anisoyl-GABA